Adverum Biotechnologies, Inc. ADVM
Set alert
4.36 USD 0.00 0.00%
At close · Dec 9
4.49 +0.13 +2.98%
After hours · Dec 9, 4:00 PM ET
4.24 Day range 4.36
52-week range unavailable
- YTD
- -6.64%
- 1 year
- -26.23%
- Open
- 4.24
- Prev close
- 4.36
- Mkt cap
- 98.60M
- Vol
- 675.98K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.24
- High
- 4.36
- Forward P/E
- -0.89
- Beta
- 1.01
- Short ratio
- 5.53
- Inst. own
- 79.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.82
- 200-d avg
- 8.42
- 1y target
- 29.71
2Y chart
Events in this range
- Mar 18, 2024Earnings: -2.3; estimate -2.8; surprise 17.86%
- Mar 21, 2024Split: 1 for 10
- May 9, 2024Earnings: -1.5; estimate -1.28; surprise -17.19%
- Jul 18, 2024Rating: Chardan Capital · Buy → Buy
- Aug 12, 2024Earnings: -0.89; estimate -1.27; surprise 29.92%
- Aug 13, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Aug 13, 2024Rating: HC Wainwright& Co. · Buy → Buy
- Aug 14, 2024Rating: Truist Securities · Buy → Buy
- Nov 4, 2024Earnings: -1.3; estimate -1.2; surprise -8.33%
- Nov 5, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Nov 19, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (73)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 24, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 19, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| MACD: Buy Signal | May 27, 2025 | 1 year ago |
| RSI: Oversold | May 14, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 29, 2025 | 1 year ago |
| RSI: Oversold | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 6, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 28, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 25, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 21, 2025 | 1 year ago |
| RSI: Oversold | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
| RSI: Oversold | Nov 19, 2024 | 1 year ago |
| SMA: Bearish | Nov 14, 2024 | 1 year ago |
| SMA: Bullish | Nov 1, 2024 | 1 year ago |
| SMA: Bearish | Oct 31, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 3, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 3, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 25, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bullish | Sep 19, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 9, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 6, 2024 | 2 years ago |
| SMA: Bearish | Aug 27, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 23, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| RSI: Overbought | Jul 18, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| RSI: Oversold | Jun 18, 2024 | 2 years ago |
| RSI: Oversold | Jun 11, 2024 | 2 years ago |
| RSI: Oversold | Jun 4, 2024 | 2 years ago |
| RSI: Oversold | May 30, 2024 | 2 years ago |
| MACD: Buy Signal | May 28, 2024 | 2 years ago |
| MACD: Sell Signal | May 17, 2024 | 2 years ago |
| RSI: Oversold | May 13, 2024 | 2 years ago |
| MACD: Buy Signal | May 1, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 24, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 22, 2024 | 2 years ago |
| RSI: Oversold | Apr 12, 2024 | 2 years ago |
| SMA: Bearish | Mar 20, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 21, 2024 | 2 years ago |
| RSI: Overbought | Feb 1, 2024 | 2 years ago |
| RSI: Overbought | Jan 29, 2024 | 2 years ago |
Key statistics
- Market cap
- 98.60M
- Enterprise value
- 18.63M
- Trailing P/E
- 0.00
- Forward P/E
- -0.89
- PEG ratio
- 0.00
- Price / sales
- 98.60
- Price / book
- 0.68
- EPS (TTM)
- -5.95
- Beta
- 1.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.00M
- Revenue growth
- 0.00%
- Free cash flow
- -47.60M
- Total cash
- 153.24M
- Total debt
- 73.26M
- Return on equity
- -76.26%
- Shares outstanding
- 20.80M
- Short % of float
- 6.57%
- 50-day average
- 6.82
- 200-day average
- 8.42
Analyst view
Consensus: none
Price target (mean) 29.71 +581.5% upside
Now 4.36
- Target (low)
- 10.00
- Target (mean)
- 29.71
- Target (high)
- 40.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.39.
Financials — quick view
ADVM Revenue — quarterly 0
ADVM Net income — quarterly -47.65M
ADVM EPS — quarterly -2.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -1.20 | -1.30 | -0.10 | -8.33% |
| Aug 12, 2024 | Jun 1, 2024 | -1.27 | -0.89 | +0.38 | +29.92% |
| May 9, 2024 | Mar 1, 2024 | -1.28 | -1.50 | -0.22 | -17.19% |
| Mar 18, 2024 | Dec 1, 2023 | -2.80 | -2.30 | +0.50 | +17.86% |
| Nov 9, 2023 | Sep 1, 2023 | -3.00 | -3.30 | -0.30 | -10.00% |
| Aug 10, 2023 | Jun 1, 2023 | -3.20 | -3.10 | +0.10 | +3.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 5, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Aug 14, 2024 | Truist Securities | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright& Co. | reit | Buy | Buy |
| Aug 13, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Jul 18, 2024 | Chardan Capital | main | Buy | Buy |
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adverum.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ADVM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FISCHER LAURENT D M.D. | Chief Executive Officer | Sale | Mar 14, 2023 | 692,141 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 29, 2024 | 0 |
| LUPHER MARK L. JR., PH.D. | Director | Purchase | Feb 6, 2024 | 0 |
| RILEY BRIGIT | Officer | Sale | Mar 14, 2023 | 117,435 |
| RUBINSTEIN LINDA M. | Chief Financial Officer | Purchase | Jun 6, 2023 | 100,000 |
| SCOPA JAMES PAUL | Director | Purchase | Feb 6, 2024 | 103,334 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 10.90% | 2,268,064 | 10.75M | Sep 29, 2024 |
| TCG Crossover Management, LLC | 9.65% | 2,008,339 | 9.52M | Sep 29, 2024 |
| Franklin Resources, Inc. | 8.46% | 1,760,056 | 8.34M | Sep 29, 2024 |
| Blackrock Inc. | 7.17% | 1,490,709 | 7.07M | Sep 29, 2024 |
| VR Adviser, LLC | 7.05% | 1,467,048 | 6.95M | Sep 29, 2024 |
| Frazier Life Sciences Management, L.P. | 5.14% | 1,069,244 | 5.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 3.00% | 624,737 | 2.96M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.82% | 586,245 | 2.78M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.61% | 543,653 | 2.58M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.37% | 285,796 | 1.35M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 211,580 | 1.00M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.93% | 192,615 | 913.00K | Oct 30, 2024 |